Omada Adds Cholesterol Care to Its Integrated Platform, Addressing the Silent Driver of Cardiovascular Risk

Rhea-AI Summary

Omada Health (Nasdaq: OMDA) expanded its virtual care platform on Feb 19, 2026 to add Omada for Cholesterol, integrating cholesterol management with weight, glucose, blood pressure, and GLP-1 support.

The program uses human-led coaching amplified by AI, multidisciplinary teams, and medication adherence guidance to support day-to-day behavior change. According to Omada, up to 70% of adults with obesity have high cholesterol and only 41% of U.S. adults with atherosclerotic cardiovascular disease reached LDL-C <70 mg/dL.

Positive

• Platform expansion adds dedicated cholesterol management to existing cardiometabolic care
• Integrated care combines weight, glucose, blood pressure, GLP-1 and cholesterol support
• Multidisciplinary teams with coaches and cardiometabolic specialists for medication adherence and behavior change
• Quick deployment leveraging existing infrastructure to meet employer demand

Negative

• No quantified clinical outcomes for Omada for Cholesterol published in this announcement
• Launch cites a single "market-leading employer" customer but provides no payer or revenue metrics

News Market Reaction – OMDA

+1.45%

1 alert

+1.45% News Effect

On the day this news was published, OMDA gained 1.45%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Adults with obesity and high cholesterol: Up to 70% ASCVD patients at healthy LDL-C: 41% Healthy LDL-C threshold: <70 mg/dL +5 more

8 metrics

Adults with obesity and high cholesterol Up to 70% Prevalence among adults with obesity cited in article

ASCVD patients at healthy LDL-C 41% U.S. adults with ASCVD reaching LDL-C <70 mg/dL

Healthy LDL-C threshold <70 mg/dL Target LDL-C level referenced for ASCVD patients

Q4 2025 revenue $72M–$74M Preliminary, unaudited Q4 2025 revenue

FY2025 revenue $256M–$258M Preliminary, unaudited full-year 2025 revenue

Revenue growth Q4 2025 50%–54% YoY Year-over-year growth range for Q4 2025 revenue

Members as of Dec 31, 2025 886,000 Total members reported in preliminary results

Andreessen Horowitz stake 5.5% and 0.5% Ownership of Omada common stock by AH funds as of Dec 31, 2025

Market Reality Check

Price: $12.95 Vol: Volume 929,606 vs 20-day ...

normal vol

$12.95 Last Close

Volume Volume 929,606 vs 20-day average 1,284,998 (relative volume 0.72x) indicates no unusual trading activity ahead of this news. normal

Technical Shares at $11.72 are trading below the $19.01 200-day MA and sit 58.73% under the 52-week high, though still 14.01% above the 52-week low.

Peers on Argus

OMDA’s gain of 2.27% aligns with meaningful strength in close peers: GDRX +6.73%...

OMDA’s gain of 2.27% aligns with meaningful strength in close peers: GDRX +6.73%, OMCL +3.9%, SDGR +2.79%, TDOC +2.64%, and PHR +2.2%, suggesting a broader positive tone in health information and virtual-care names rather than a purely isolated move.

Historical Context

5 past events · Latest: Feb 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Earnings date set	Neutral	-2.1%	Announcement of Q4 and FY2025 results release and conference call timing.
Jan 12	Prelim revenue update	Positive	+4.6%	Strong preliminary Q4 and FY2025 revenue growth and member expansion disclosure.
Jan 08	GLP-1 outcomes data	Positive	-0.8%	Real-world GLP-1 companion data showing durable, double‑digit percentage weight loss.
Dec 22	JPM conference	Neutral	+6.8%	Participation announcement for the 44th Annual J.P. Morgan Healthcare Conference.
Nov 20	Evercore conference	Neutral	-4.9%	Participation and fireside chat at the Evercore Healthcare Conference for investor outreach.

Pattern Detected

News and event headlines have produced mixed reactions, with strong preliminary revenue data aligning positively while product and conference updates have seen both positive and negative follow-through.

Recent Company History

Over the last six months, Omada has focused on investor visibility and growth proof-points. Preliminary Q4 and FY2025 revenue of $72M–$74M and $256M–$258M with ~50%+ YoY growth and 886,000 members highlighted strong topline momentum. Multiple conference appearances, including J.P. Morgan and Evercore, emphasized outreach to institutional investors. A GLP-1 behavior-change analysis showed durable weight loss but drew a modest negative reaction. Against this backdrop, adding dedicated cholesterol care extends the cardiometabolic platform beyond prior GLP-1-focused messaging.

Market Pulse Summary

This announcement adds dedicated cholesterol management to Omada’s existing virtual cardiometabolic ...

Analysis

This announcement adds dedicated cholesterol management to Omada’s existing virtual cardiometabolic platform, targeting gaps where only 41% of adults with atherosclerotic cardiovascular disease achieve LDL-C <70 mg/dL. It builds on prior GLP-1 and lifestyle programs while leveraging human-led coaching and AI. In context of strong preliminary FY2025 revenue of $256M–$258M and 886,000 members, key factors to watch include engagement metrics, employer adoption, and clinical outcome data from the new cholesterol offering.

Key Terms

LDL-C, atherosclerotic cardiovascular disease, GLP-1, cardiometabolic

4 terms

LDL-C medical

"only 41% ever reached a healthy LDL-C level (<70 mg/dL)."

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

atherosclerotic cardiovascular disease medical

"among U.S. adults with atherosclerotic cardiovascular disease, only 41% ever reached"

Atherosclerotic cardiovascular disease is the chronic narrowing and hardening of arteries caused by buildup of fatty plaques, like pipes gradually clogged by residue, which reduces blood flow to the heart, brain and other organs. It matters to investors because it is a leading driver of demand for drugs, medical devices, diagnostics and long‑term care—and outcomes from clinical trials, approvals or changes in treatment guidelines can quickly affect the market value of companies serving this large, costly area of medicine.

GLP-1 medical

"include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support."

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

cardiometabolic medical

"the same interconnected cardiometabolic system as weight, blood pressure, and diabetes,"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

AI-generated analysis. Not financial advice.

Omada for Cholesterol closes a critical gap in cardiovascular care, delivering between-visit support for the many adults whose LDL remains uncontrolled under usual care¹

SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, today announced the expansion of its integrated platform to include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support. Up to 70% of adults with obesity have high cholesterol,¹ yet among U.S. adults with atherosclerotic cardiovascular disease, only 41% ever reached a healthy LDL-C level (<70 mg/dL).² This gap underscores a core challenge in traditional care models that are not designed to sustain the day-to-day behaviors required to improve cholesterol numbers over time.

“High cholesterol rarely exists in isolation^1,3,4 and is a primary driver of cumulative cardiovascular risk,⁵ yet it is often managed episodically or without sustained support,¹” said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. “When we help members improve their cholesterol through behavior change and medication adherence, we’re not just improving lipid levels; we’re meaningfully lowering cumulative cardiovascular risk and the likelihood of costly, acute events like heart attacks and strokes.^6,7 Evidence from Omada’s lifestyle change programs has already shown that virtual, behavior-first interventions can improve multiple cardiometabolic risk factors, including cholesterol, underscoring the importance of adding dedicated cholesterol support to our care model.⁸”

High cholesterol is a core driver of cardiovascular risk⁵, yet standard care still manages it through periodic labs and brief visits¹ rather than day‑to‑day support. Omada for Cholesterol is built on Omada’s compassionate intelligence model of human-led coaching amplified by AI to address cholesterol as part of the same interconnected cardiometabolic system as weight, blood pressure, and diabetes, instead of another siloed benefit. Multidisciplinary care teams, including health coaches and cardiometabolic specialists, connect nutrition, activity, behavior change support, and medication adherence guidance to help members’ reach their cholesterol goals.

“Launching with a market-leading employer is a signal that there is a need for between-visit cholesterol care that properly addresses long-term cardiovascular risk in their populations,” said Sean Duffy, CEO & Co‑Founder of Omada Health. “Because of our flexible infrastructure, we were able to quickly add cholesterol support on our existing platform, giving customers one partner for integrated cardiometabolic care in response to their demand.”

Omada for Cholesterol is designed to complement primary and specialty care by addressing how cardiovascular risk builds over time, not just how it’s measured in visits. By keeping members engaged in day-to-day behavior change across nutrition, activity, and medication adherence, Omada helps bend the curve of cardiovascular disease, rather than reacting only after acute events occur.

About Omada Health
Omada Health (Nasdaq: OMDA) is on a mission to fix what’s broken in chronic care. Today's healthcare system poorly serves chronic conditions that require ongoing support between doctor visits, like obesity, diabetes, hypertension, and musculoskeletal disorders. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than one million members since launch across 2,000+ employers, health plans, and health systems. Learn more at omadahealth.com.

Contacts
Rose Ramseth
press@omadahealth.com

Citations

1. Lim Y, Haq N, Boster J. Obesity and comorbid conditions. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK574535/.
2. MacDougall DE, Ferdinand K, Baum SJ, et al. Cholesterol management in US adults with ASCVD in the Family Heart Database during 2022–23: Current state of care and opportunities for improvement. Am J Prev Cardiol. 2025;24:101354. doi:10.1016/j.ajpc.2025.101354.
3. American Heart Association. Know your risk factors for high blood pressure. Available at: https://www.heart.org/en/health-topics/high-blood-pressure/know-your-risk-factors-for-high-blood-pressure. Accessed February 12, 2026.
4. Centers for Disease Control and Prevention. Prevalence of self-reported high cholesterol in adults with diabetes, aged 18 years or older, United States, 2021. Behavioral Risk Factor Surveillance System. Available at: https://nccd.cdc.gov/Toolkit/DiabetesBurden/SelfReported/Hc. Accessed February 12, 2026.
5. American Heart Association. Prevention and treatment of high cholesterol (hyperlipidemia). Available at: https://www.heart.org/en/health-topics/cholesterol/prevention-and-treatment-of-high-cholesterol-hyperlipidemia. Accessed February 12, 2026.
6. American Heart Association. Lifestyle changes to prevent a heart attack. Available at: https://www.heart.org/en/health-topics/heart-attack/life-after-a-heart-attack/lifestyle-changes-for-heart-attack-prevention. Accessed February 12, 2026.
7. Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2026;[Epub ahead of print].
8. Castro Sweet CM, Chiguluri V, Gumpina R, et al. Outcomes of a Digital Health Program With Human Coaching for Diabetes Risk Reduction in a Medicare Population. J Aging Health. 2018;30(5):692-710. doi:10.1177/0898264316688791

FAQ

What is Omada Health announcing about cholesterol care on Feb 19, 2026 (OMDA)?

Omada launched Omada for Cholesterol to add dedicated cholesterol management to its platform. According to Omada, the program integrates coaching, AI, and multidisciplinary teams to support day-to-day behavior change alongside weight, glucose, blood pressure, and GLP-1 support.

How does Omada for Cholesterol aim to improve LDL levels for members (OMDA)?

The program focuses on sustained behavior change, medication adherence, and specialist coaching to lower LDL over time. According to Omada, human-led coaching amplified by AI connects nutrition, activity, and medication guidance to address cumulative cardiovascular risk.

What data does Omada cite about population cholesterol gaps in the Feb 19, 2026 announcement (OMDA)?

Omada cites that up to 70% of adults with obesity have high cholesterol and only 41% of U.S. adults with ASCVD ever reached LDL-C <70 mg/dL. According to Omada, these figures illustrate gaps in usual care that the program targets.

Who will deliver Omada for Cholesterol care and how is it integrated with other services (OMDA)?

Care is delivered by multidisciplinary teams including health coaches and cardiometabolic specialists, linked with AI tools. According to Omada, the service ties nutrition, activity, behavior change, and medication adherence into a single, integrated offering.

Which customers are using Omada for Cholesterol at launch and what does that indicate for OMDA?

Omada says the product launched with a "market-leading employer," signaling employer demand for between-visit cholesterol care. According to Omada, the initial deployment used its flexible infrastructure to add cholesterol support quickly for customers.